Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib

Martin Reck,1 Anders Mellemgaard2 1Department of Thoracic Oncology, Lung Clinic Grosshansdorf, and member of the Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 2Department of Oncology, Herlev University Hospital, Copenhagen, Denmark Abstract: There remains an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Reck M, Mellemgaard A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ffd7330ca7a744448e8bcf097c506ff0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ffd7330ca7a744448e8bcf097c506ff0
record_format	dspace
spelling	oai:doaj.org-article:ffd7330ca7a744448e8bcf097c506ff02021-12-02T06:06:14ZEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib1177-5491https://doaj.org/article/ffd7330ca7a744448e8bcf097c506ff02015-07-01T00:00:00Zhttp://www.dovepress.com/emerging-treatments-and-combinations-in-the-management-of-nsclc-clinic-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Martin Reck,1 Anders Mellemgaard2 1Department of Thoracic Oncology, Lung Clinic Grosshansdorf, and member of the Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 2Department of Oncology, Herlev University Hospital, Copenhagen, Denmark Abstract: There remains an unmet need for effective, well-tolerated treatment options in advanced non-small cell lung cancer (NSCLC) to alleviate the disease burden for a broad selection of patients. Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and was recently approved in Europe for use in combination with docetaxel for the treatment of adults with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology, following first-line chemotherapy. Nintedanib has been investigated extensively in preclinical research and in a number of clinical studies, the most important of which was the Phase III LUME-Lung 1 study, which investigated nintedanib in combination with docetaxel in patients with advanced NSCLC after failure of first-line chemotherapy. In this study, which led to the approval of nintedanib, addition of nintedanib to docetaxel significantly improved overall survival in patients with adenocarcinoma histology. Nintedanib demonstrated a manageable safety profile in combination with docetaxel. This review focuses on the clinical experience with nintedanib in NSCLC and discusses the clinical potential of this agent for use in combination with chemotherapy. Keywords: nintedanib, non-small cell lung cancer, second-line treatment, docetaxel, adenocarcinoma, antiangiogenesisReck MMellemgaard ADove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 47-56 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Reck M Mellemgaard A Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
description	Martin Reck,1 Anders Mellemgaard2 1Department of Thoracic Oncology, Lung Clinic Grosshansdorf, and member of the Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 2Department of Oncology, Herlev University Hospital, Copenhagen, Denmark Abstract: There remains an unmet need for effective, well-tolerated treatment options in advanced non-small cell lung cancer (NSCLC) to alleviate the disease burden for a broad selection of patients. Nintedanib is a potent, oral, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and was recently approved in Europe for use in combination with docetaxel for the treatment of adults with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology, following first-line chemotherapy. Nintedanib has been investigated extensively in preclinical research and in a number of clinical studies, the most important of which was the Phase III LUME-Lung 1 study, which investigated nintedanib in combination with docetaxel in patients with advanced NSCLC after failure of first-line chemotherapy. In this study, which led to the approval of nintedanib, addition of nintedanib to docetaxel significantly improved overall survival in patients with adenocarcinoma histology. Nintedanib demonstrated a manageable safety profile in combination with docetaxel. This review focuses on the clinical experience with nintedanib in NSCLC and discusses the clinical potential of this agent for use in combination with chemotherapy. Keywords: nintedanib, non-small cell lung cancer, second-line treatment, docetaxel, adenocarcinoma, antiangiogenesis
format	article
author	Reck M Mellemgaard A
author_facet	Reck M Mellemgaard A
author_sort	Reck M
title	Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
title_short	Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
title_full	Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
title_fullStr	Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
title_full_unstemmed	Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
title_sort	emerging treatments and combinations in the management of nsclc: clinical potential of nintedanib
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/ffd7330ca7a744448e8bcf097c506ff0
work_keys_str_mv	AT reckm emergingtreatmentsandcombinationsinthemanagementofnsclcclinicalpotentialofnintedanib AT mellemgaarda emergingtreatmentsandcombinationsinthemanagementofnsclcclinicalpotentialofnintedanib
_version_	1718400090881654784

Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib

Ejemplares similares